Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lee's Pharmaceutical HoldingsLPCUF 74 Debt-to-EBITDA is 9.29 as of Dec. 2025, which is 1329% above its 10-year median of 0.65. GuruFocus rates LPCUF with a GF Score™ of 74/100 and a GF Value™ of $0.28. The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, Lee's Pharmaceutical Holdings ranks worse than 74.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Lee's Pharmaceutical Holdings's Debt-to-EBITDA or its related term are showing as below:
LPCUF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13 Med: 0.65 Max: 3.71
Current: 3.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of Lee's Pharmaceutical Holdings was 3.71. The lowest was 0.13. And the median was 0.65.
LPCUF's Debt-to-EBITDA is ranked worse than 74.74% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs LPCUF: 3.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Lee's Pharmaceutical Holdings Debt-to-EBITDA Related Terms
Lee's Pharmaceutical Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Lee's Pharmaceutical Holdings (LPCUF) has a Debt-to-EBITDA of 9.29 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lee's Pharmaceutical Holdings. This is 1329% above median its historical median of 0.65. Over the past decade, Lee's Pharmaceutical Holdings' Debt-to-EBITDA has ranged from 0.13 to 3.71. According to the industry distribution chart, Lee's Pharmaceutical Holdings ranks #512 out of 685 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Lee's Pharmaceutical Holdings' Debt-to-EBITDA too high?
Lee's Pharmaceutical Holdings' current Debt-to-EBITDA of 9.29 is 1329% above median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 3.71. The Drug Manufacturers industry median Debt-to-EBITDA is 1.58. Lee's Pharmaceutical Holdings' value of 9.29 is 488% above this industry median. Based on the distribution chart, Lee's Pharmaceutical Holdings ranks #512 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lee's Pharmaceutical Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Lee's Pharmaceutical Holdings' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lee's Pharmaceutical Holdings ranks #512 out of 685 companies for Debt-to-EBITDA. This places Lee's Pharmaceutical Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.58. Lee's Pharmaceutical Holdings' value of 9.29 is 488% above this benchmark. Historically, Lee's Pharmaceutical Holdings' own Debt-to-EBITDA has ranged from 0.13 to 3.71 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 1.58, Lee's Pharmaceutical Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lee's Pharmaceutical Holdings's current Debt-to-EBITDA of 9.29 is 488% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lee's Pharmaceutical Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lee's Pharmaceutical Holdings's current Debt-to-EBITDA is 9.29, which is 1329% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lee's Pharmaceutical Holdings stock overvalued right now?
Lee's Pharmaceutical Holdings (LPCUF) has a current Debt-to-EBITDA of 9.29. The stock's GF Value™ is $0.28, compared to a current price of $0.19 — trading 32% below its estimated fair value. The current Debt-to-EBITDA is 9.29, which is 1329% above median its 10-year median of 0.65 and 488% above the Drug Manufacturers industry median of 1.58. Lee's Pharmaceutical Holdings' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Lee's Pharmaceutical Holdings (LPCUF), the current Debt-to-EBITDA is 9.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lee's Pharmaceutical Holdings (LPCUF) Overvalued in 2026?
Based on GuruFocus' analysis, Lee's Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of $0.19 is trading 32% below its estimated GF Value™ of $0.28.
Key valuation signals for LPCUF:
Debt-to-EBITDA: 9.29 (1329% above median its 10-year median of 0.65)
GF Value™: $0.28 vs. price of $0.19 (32% below fair value)
Industry Position: 488% above the Drug Manufacturers median (#512 of 685)
No single metric tells the full story. See the LPCUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
74GF Score
Get the complete analysis for LPCUF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LPCUF has been successfully added to your 
